Ocrelizumab is currently the only approved treatment for primary progressive multiple sclerosis and relapsing multiple sclerosis with a twice-yearly dosing regimen that patients are likely to prefer over alternatives that typically involve monthly injections or daily doses, Roche officials said
The health ministry said the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers had conducted “risk-based inspections” of 275 premises, which led to more than 250 actions such as showcause notices, stop-production orders, suspensions and licence cancellations
What's NexCAR19 and other cutting-edge technologies for cancer care in India? Add the term to your current affairs glossary of Science & Tech and fasten your seat belt for UPSC CSE 2024.